Content area
Full text
Seeing demand for payer expertise
Andrew Gottfried, managing partner, director of client services at Entrée Health, doesn't mince words when he describes 2014 as a "challenging year." At the beginning of 2013, corporate parent CDM Group spun off part of Entrée Health into Entrée Health Princeton, which almost immediately began to operate independently of its former agency. The spin-off had the consequence of concentrating most of the elder firm's work in a single client, Novo Nordisk.
You can guess what happened next. When Novo shifted part of its business elsewhere, Entrée felt some pain. "That was a longstanding relationship for us, and it created a challenge financially and culturally," Gottfried admits. The agency faced another setback in 2014 due to the delay of two Amgen cardiovascular drugs: Corlanor for congestive heart failure, which was just released, and cholesterol-lowering PCSK9 inhibitor Repatha, which is expected to launch in the next few months.
Despite those challenges, Entrée has an optimistic outlook for the rest...